27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
TORONTO , May 26, 2022 /CNW/ - Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX:MDP) shares his Company's story in an interview with TMX Group.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View From The C-Suite visit https://www.tmxmoney.com/en/csuite.html.
About Medexus Pharmaceuticals, (TSX:MDP)
Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Their current focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy. They continue to build a highly differentiated company with a growing portfolio of innovative and high-value orphan and rare disease products that will underpin their growth for the next decade.
SOURCE Toronto Stock Exchange
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.